Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Entrada Therapeutics Inc shares valued at $202,554 were sold by PARMAR KUSH on Jul 09 ’25. At $7.50 per share, PARMAR KUSH sold 27,000 shares. The insider’s holdings dropped to 1,093,313 shares worth approximately $5.56 million following the completion of this transaction.
Also, 5AM Ventures V, L.P. sold 20,065 shares, netting a total of over 150,528 in proceeds. Following the sale of shares at $7.50 each, the insider now holds 3,163,066 shares.
Before that, 5AM Ventures V, L.P. had sold 6,935 shares from its account. In a trade valued at $52,026, the 10% Owner traded Entrada Therapeutics Inc shares for $7.50 each. Upon closing the transaction, the insider’s holdings decreased to 6,935 shares, worth approximately $5.56 million.
As published in their initiating research note from ROTH MKM on December 06, 2024, Entrada Therapeutics Inc [TRDA] has been a Buy and the price target has been revised to $29. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early January. As of April 03, 2023, H.C. Wainwright has initiated its “Buy” rating for TRDA.
Analyzing TRDA Stock Performance
On last trading session, Entrada Therapeutics Inc [NASDAQ: TRDA] plunged -0.59% to $5.09. The stock’s lowest price that day was $5.04, but it reached a high of $5.505 in the same session. During the last five days, there has been a drop of approximately -2.49%. Over the course of the year, Entrada Therapeutics Inc shares have dropped approximately -66.07%.
Is Entrada Therapeutics Inc subject to short interest?
Stocks of Entrada Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by 65093.0 shares to 1.08 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 1.15 million shares. A decline of -6.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.28 of the overall float, the days-to-cover ratio (short ratio) decline to 4.28.
Which companies own the most shares of Entrada Therapeutics Inc (TRDA)?
In terms of Entrada Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21.5 in the next 12 months, up nearly 319.92% from the previous closing price of $5.12. Analysts anticipate Entrada Therapeutics Inc stock to reach 23 by 2025, with the lowest price target being 20. In spite of this, 3 analysts ranked Entrada Therapeutics Inc stock as Buy at the end of 2025.
